1. Home
  2. TNGX vs CLCO Comparison

TNGX vs CLCO Comparison

Compare TNGX & CLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • CLCO
  • Stock Information
  • Founded
  • TNGX 2014
  • CLCO 2018
  • Country
  • TNGX United States
  • CLCO United Kingdom
  • Employees
  • TNGX N/A
  • CLCO 1647
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • CLCO
  • Sector
  • TNGX Health Care
  • CLCO
  • Exchange
  • TNGX Nasdaq
  • CLCO Nasdaq
  • Market Cap
  • TNGX 413.6M
  • CLCO 417.5M
  • IPO Year
  • TNGX N/A
  • CLCO N/A
  • Fundamental
  • Price
  • TNGX $3.04
  • CLCO $7.77
  • Analyst Decision
  • TNGX Strong Buy
  • CLCO
  • Analyst Count
  • TNGX 8
  • CLCO 0
  • Target Price
  • TNGX $13.14
  • CLCO N/A
  • AVG Volume (30 Days)
  • TNGX 1.5M
  • CLCO 331.0K
  • Earning Date
  • TNGX 11-06-2024
  • CLCO 11-20-2024
  • Dividend Yield
  • TNGX N/A
  • CLCO 7.80%
  • EPS Growth
  • TNGX N/A
  • CLCO N/A
  • EPS
  • TNGX N/A
  • CLCO 1.73
  • Revenue
  • TNGX $43,383,000.00
  • CLCO $333,653,000.00
  • Revenue This Year
  • TNGX $27.73
  • CLCO N/A
  • Revenue Next Year
  • TNGX N/A
  • CLCO $11.80
  • P/E Ratio
  • TNGX N/A
  • CLCO $4.49
  • Revenue Growth
  • TNGX 15.67
  • CLCO N/A
  • 52 Week Low
  • TNGX $2.70
  • CLCO $6.92
  • 52 Week High
  • TNGX $13.01
  • CLCO $13.68
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 39.30
  • CLCO 42.64
  • Support Level
  • TNGX $2.72
  • CLCO $6.92
  • Resistance Level
  • TNGX $3.29
  • CLCO $7.48
  • Average True Range (ATR)
  • TNGX 0.30
  • CLCO 0.27
  • MACD
  • TNGX 0.07
  • CLCO 0.14
  • Stochastic Oscillator
  • TNGX 32.08
  • CLCO 86.68

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.

About CLCO Cool Company Ltd.

Cool Co Ltd is a LNG shipping company. The company is engaged in the acquisition, ownership, operation and chartering of liquefied natural gas (LNG) carriers (LNGCs), and the operation of third party fleets under management agreements.

Share on Social Networks: